Reconsidering α-Blockade for the Management of Hypertension in Patients With CKD

Between 60% and 90% of individuals with chronic kidney disease (CKD) have hypertension, with a higher prevalence of hypertension as kidney function worsens.1 Compared with the general population, a disproportionate number of patients with CKD have treatment-resistant hypertension (elevated blood pressure despite treatment with at least 3 antihypertensives or requiring a fourth medication to achieve blood pressure control)2 and refractory hypertension (uncontrolled hypertension receiving≥5 antihypertensives).